Evidence mapPaperPMID 32178279Full record

Trial reportNutrients2020

Comparison of Omega-3 Eicosapentaenoic Acid Versus Docosahexaenoic Acid-Rich Fish Oil Supplementation on Plasma Lipids and Lipoproteins in Normolipidemic Adults.

Zhi-Hong Yang, Marcelo Amar, Maureen Sampson, Amber B Courville, Alexander V Sorokin, Scott M Gordon, Angel M Aponte, Michael Stagliano, Martin P Playford, Yi-Ping Fu and 3 more

Open access · goldAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Nutrients, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. COVID-19-Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020
    Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Zhi-Hong YangLipoprotein Metabolism Section, Translational Vascular Medicine Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD 20892-1666, USA.ORCID 0000-0002-1885-3162
Marcelo AmarLipoprotein Metabolism Section, Translational Vascular Medicine Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD 20892-1666, USA.
Maureen SampsonClinical Center, Department of Laboratory Medicine, NIH, Bethesda, MD 20814, USA.
Amber B CourvilleClinical Center, Nutrition Department, NIH, Bethesda, MD 20814, USA.ORCID 0000-0002-1419-3937
Alexander V SorokinLipoprotein Metabolism Section, Translational Vascular Medicine Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD 20892-1666, USA.ORCID 0000-0002-2291-4888
Scott M GordonLipoprotein Metabolism Section, Translational Vascular Medicine Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD 20892-1666, USA.
Angel M AponteProteomics Core, Cardiovascular Branch, NHLBI, NIH, Bethesda, MD 20814, USA.
Michael StaglianoLipoprotein Metabolism Section, Translational Vascular Medicine Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD 20892-1666, USA.
Martin P PlayfordSection of Inflammation and Cardiometabolic Diseases, Cardiovascular Branch, NHLBI, NIH, Bethesda, MD 20814, USA.
Yi-Ping FuOffice of Biostatistics Research, NHLBI, NIH, Bethesda, MD 20814, USA.
Shanna YangClinical Center, Nutrition Department, NIH, Bethesda, MD 20814, USA.
Nehal N MehtaSection of Inflammation and Cardiometabolic Diseases, Cardiovascular Branch, NHLBI, NIH, Bethesda, MD 20814, USA.
Alan T RemaleyLipoprotein Metabolism Section, Translational Vascular Medicine Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD 20892-1666, USA.
National Institutes of Health · USCancer Research And Biostatistics · USNational Institutes of Health Clinical Center · US

Funding

NIH HHS Intramural Research Program of the National Heart, Lung and Blood Institute (NHLBI) (HL006095)
6 · The paper itself

Abstract

backgroundEicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have both shared and different cardiovascular effects, and commonly used fish oil supplements have considerably varied EPA/DHA ratios.

aimsWe compared the effects of fish oil supplements with different EPA/DHA ratios on lipoprotein metabolism.

methodsIn a double-blind, randomized cross-over study, normolipidemic adults (n = 30) consumed 12 g/day of EPA-rich (EPA/DHA: 2.3) or DHA-rich (EPA/DHA: 0.3) fish oil for 8-weeks, separated by an 8-week washout period.

resultsBoth fish oil supplements similarly lowered plasma TG levels and TG-related NMR parameters versus baseline (

conclusionsOverall, fish oil supplements with varied EPA/DHA ratios had similar effects on total lipids/lipoproteins, but differences were observed in lipoprotein subfraction composition and distribution, which could impact on the use of EPA versus DHA for improving cardiovascular health.

Indexed as

AdultCross-Over StudiesDocosahexaenoic AcidsDouble-Blind MethodEicosapentaenoic AcidFemaleHumansLipoproteins, HDLLipoproteins, LDLMaleTriglyceridesDocosahexaenoic AcidsEicosapentaenoic AcidLipoproteins, HDLLipoproteins, LDLTriglyceridesdocosahexaenoic acid (DHA)eicosapentaenoic acid (EPA)HDL cholesterolLDL cholesterollipoprotein metabolismomega-3 fatty acidstriglyceride

Identifiers

PMID32178279
PMCPMC7146314
OpenAlexW3011584069

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.